We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Medarex Receives Milestone Payment From ImClone
News

Medarex Receives Milestone Payment From ImClone

Medarex Receives Milestone Payment From ImClone
News

Medarex Receives Milestone Payment From ImClone

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Medarex Receives Milestone Payment From ImClone"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Medarex, Inc. has announced that it received a milestone payment from its licensing partner, ImClone Systems Incorporated, following the acceptance of an Investigational New Drug (IND) application for a fully human IgG1 antibody for the treatment of cancer.

The antibody was developed using Medarex's UltiMAb® technology. Medarex may receive future milestone payments and royalties should this product candidate progress through clinical development and to the market.

"We believe that the advancement of the ImClone Systems' antibody into clinical trials further demonstrates the strength of Medarex's UltiMAb technology," said Donald L. Drakeman, President and CEO of Medarex.

"With the broadening use of our UltiMAb platform, we expect to see a continual movement of new product candidates into clinical trials that goes beyond the thirty candidates currently in clinical development by us and our partners."

Advertisement